Search Result

Results for "

non-ATP

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (1) Apoptosis (6) Aurora Kinase (2) Autophagy (4) Bcr-Abl (2) Beta-secretase (1) Casein Kinase (1) ERK (1) Eukaryotic Initiation Factor (eIF) (1) FGFR (1) FLT3 (1) GSK-3 (1) Influenza Virus (2) MAPKAPK2 (MK2) (1) MEK (8) Mitophagy (3) PAK (1) PI3K (5) Polo-like Kinase (PLK) (4) SARS-CoV (1) Src (2)
By Research Areas:	Cancer (22) Inflammation/Immunology (1) Neurological Disease (3)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Natural
Products

Targets Recommended: ATP Synthase ATP Citrate Lyase P-glycoprotein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12031

U0126-EtOH Maximum Cited Publications 331 Publications Verification	MEK Autophagy Mitophagy Influenza Virus	Cancer
U0126 (U0126-EtOH) is a potent, non-ATP competitive and selective MEK1 and MEK2 inhibitor, with IC₅₀s of 72 nM and 58 nM, respectively. U0126 is an autophagy and mitophagy inhibitor .

HY-11007

GNF-2 2 Publications Verification	Bcr-Abl SARS-CoV	Cancer
GNF-2 is a highly selective, allosteric, non-ATP competitive inhibitor of Bcr-Abl. GNF-2 inhibits Ba/F3.p210 proliferation with an IC₅₀ of 138 nM .

HY-12134

Poloxin 3 Publications Verification	Polo-like Kinase (PLK)	Cancer
Poloxin is a non-ATP competitive Polo-like Kinase 1 (PLK1) inhibitor that targets the polo-box domain, with an IC₅₀ of appr 4.8 μM.

HY-111184

PIK-108

PI3K Cancer

PIK-108 is a non-ATP competitive, allosteric p110β/p110δ selective inhibitor .
HY-15663

IPA-3

10+ Cited Publications

PAK Cancer

IPA-3 is a selective non-ATP competitive PAK1 inhibitor with IC₅₀ of 2.5 μM, and shows no inhibition to group II PAKs (PAKs 4-6).

PIK-108	PI3K	Cancer
PIK-108 is a non-ATP competitive, allosteric p110β/p110δ selective inhibitor .

IPA-3 10+ Cited Publications	PAK	Cancer
IPA-3 is a selective non-ATP competitive PAK1 inhibitor with IC₅₀ of 2.5 μM, and shows no inhibition to group II PAKs (PAKs 4-6).

HY-124330

Tripolin A (E)-Tripolin A	Aurora Kinase	Others
Tripolin A ((E)-Tripolin A) is a specific non-ATP competitive Aurora A kinase inhibitor, with IC₅₀ values of 1.5 μM and 7 μM for Aurora A and Aurora B, respectively .

HY-12031A

U0126 Maximum Cited Publications 331 Publications Verification	MEK Autophagy Mitophagy Influenza Virus	Cancer
U0126 is a potent, non-ATP competitive and selective MEK1 and MEK2 inhibitor, with IC₅₀s of 72 nM and 58 nM, respectively. U0126 is an autophagy and mitophagy inhibitor .

HY-18237

KX1-004	Src	Others
KX1-004 is a potent and non-ATP competitive Src-PTK inhibitor with an IC₅₀ of 40 μM. KX1-004 protects the cochlea from hazardous noise and prevents noise-induced hearing loss (NIHL) .

HY-111383

LX2343	Beta-secretase PI3K Amyloid-β Autophagy	Neurological Disease
LX2343 is a BACE1 enzyme inhibitor with an IC₅₀ value of 11.43±0.36 μM. LX2343 acts as a non-ATP competitive PI3K inhibitor with an IC₅₀ of 15.99±3.23 μM. LX2343 stimulates autophagy in its promotion of Aβ clearance.

HY-12062

PD318088 1 Publications Verification	MEK	Cancer
PD318088 is a potent, allosteric and non-ATP competitive MEK1/2 inhibitor, an analog of PD184352 (HY-50295). PD318088 binds simultaneously with ATP in a region of the MEK1 active site that is adjacent to the ATP-binding site. PD318088 can be used for cancer research .

HY-N4042

Hirsutenone	PI3K ERK	Inflammation/Immunology Cancer
Hirsutenone is an active botanical diarylheptanoid present in Alnus species and exhibits many biological activities, including anti-inflammatory, anti-tumor promoting and anti-atopic dermatitis effects. Hirsutenone attenuates adipogenesis by binding directly to PI3K and ERK1 in a non-ATP competitive manner. Hirsutenone can be used for the study of obesity .

HY-153089

GSK3-IN-3 1 Publications Verification	GSK-3 Mitophagy	Neurological Disease
GSK3-IN-3 is a mitophagy inducer, inducing Parkin-dependent mitophagy. GSK3-IN-3 is also a GSK-3 inhibitor with an IC₅₀ value of 3.01 μM. GSK3-IN-3 is non-ATP nor substrate competitive and is neuroprotective against 6-OHDA .

HY-101544

ARQ 069	FGFR	Cancer
ARQ 069, an analog of ARQ 523, inhibits FGFR in an enantiospecific manner. ARQ 069 targets the unphosphorylated, inactive forms of FGFR1/FGFR2 kinases (IC₅₀s of 0.84 μM and 1.23 μM, respectively). ARQ 069 inhibits FGFR1/FGFR2 autophosphorylation (IC₅₀s of 2.8 and 1.9 μM, respectively) through a mechanism in a non-ATP competitive dependent manner .

HY-101513

eIF4A3-IN-1 3 Publications Verification	Eukaryotic Initiation Factor (eIF)	Cancer
eIF4A3-IN-1 (compound 53a) is a selective eukaryotic initiation factor 4A3 (eIF4A3) inhibitor (IC₅₀=0.26 μM; K_d=0.043 μM), which binds to a non-ATP binding site of eIF4A3 and shows significant cellular nonsense-mediated RNA decay (NMD) inhibition at 10 and 3 μM and can be as a probe for further study of eIF4A3, the exon junction complex (EJC), and NMD .

HY-77195

Poloxime

Polo-like Kinase (PLK) Cancer

Poloxime, a hydrolysis product of poloxin, is a non-ATP-competitive Plk1 inhibitor, with moderate Plk1 inhibitory activity.
HY-108643

CMPD1

MAPKAPK2 (MK2) Cancer

CMPD1 is a selective and non-ATP-competitive p38 MAPK-mediated MK2 phosphorylation inhibitor with apparent K_i (K_i ^app) of 330 nM .

Poloxime	Polo-like Kinase (PLK)	Cancer
Poloxime, a hydrolysis product of poloxin, is a non-ATP-competitive Plk1 inhibitor, with moderate Plk1 inhibitory activity.

CMPD1	MAPKAPK2 (MK2)	Cancer
CMPD1 is a selective and non-ATP-competitive p38 MAPK-mediated MK2 phosphorylation inhibitor with apparent K_i (K_i ^app) of 330 nM .

HY-50706

Selumetinib 55+ Cited Publications AZD6244; ARRY-142886	MEK Apoptosis	Cancer
Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC₅₀ of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.

HY-14691

Refametinib 10+ Cited Publications BAY 869766; RDEA119	MEK	Cancer
Refametinib (BAY 869766; RDEA119) is an orally available, potent, non-ATP-competitive, selective, allosteric MEK1/MEK2 inhibitor with IC₅₀s of 19 nM and 47 nM, respectively.

HY-50706A

Selumetinib sulfate 55+ Cited Publications AZD6244 sulfate; ARRY-142886 sulfate	MEK Apoptosis	Cancer
Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC₅₀ of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.

HY-10254G

Mirdametinib PD0325901; PD325901	MEK	Cancer
Mirdametinib (PD0325901) (GMP) is Mirdametinib (HY-10254) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mirdametinib is an orally active, selective and non-ATP-competitive MEK inhibitor .

HY-136532

ZT-1a	Others	Neurological Disease
ZT-1a is a potent, non-ATP-competitive and selective SPAK inhibitor. ZT-1a inhibits SPAK activity with IC₅₀s of 44.3, 35.0, 46.7 μM at ATP concentrations of 0.01, 0.1 and 1 mM, respectively .

HY-13024

Rebastinib 5+ Cited Publications DCC-2036	Bcr-Abl FLT3 Src Apoptosis	Cancer
Rebastinib (DCC-2036) is an orally active, non-ATP-competitive Bcr-Abl inhibitor for Abl1 ^WT and Abl1 ^T315I with IC₅₀s of 0.8 nM and 4 nM, respectively. Rebastinib also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit.

HY-148318

CK2α-IN-1	Casein Kinase	Cancer
CK2α-IN-1 (compound 2) is a selective CK2α inhibitor (IC₅₀=7.0 µM; K_i=1.6 µM) that exhibits a non-ATP-competitive mode of action. CK2α-IN-1 exhibits good potential for anticancer studies .

HY-10254

Mirdametinib 80+ Cited Publications PD0325901; PD325901	MEK Autophagy Apoptosis	Cancer
Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive MEK inhibitor with an IC₅₀ of 0.33 nM. Mirdametinib exhibits a K_i ^app of 1 nM against activated MEK1 and MEK2. Mirdametinib suppresses the expression of p-ERK1/2 and induces apoptosis. Mirdametinib has anti-cancer activity for a broad spectrum of human tumor xenografts .

HY-12037A

Rigosertib 5 Publications Verification ON-01910	Polo-like Kinase (PLK) PI3K Apoptosis	Cancer
Rigosertib (ON-01910) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the PI3 kinase/Akt pathway, promots the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle . Rigosertib is a selective and non-ATP-competitive inhibitor of PLK1 with an IC₅₀ of 9 nM .

HY-12037

Rigosertib sodium 5 Publications Verification ON-01910 sodium	Polo-like Kinase (PLK) PI3K Apoptosis	Cancer
Rigosertib sodium (ON-01910 sodium) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the PI3K/Akt pathway, promotes the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle . Rigosertib sodium is a selective and non-ATP-competitive inhibitor of PLK1 with an IC₅₀ of 9 nM .

HY-131339

SP-96	Aurora Kinase	Cancer
SP-96 is a highly potent, selective and non-ATP-competitive Aurora B (IC₅₀=0.316 nM) inhibitor and shows >2000 fold selectivity against FLT3 and KIT. SP-96 shows selective growth inhibition in NCI60 screening, incluing MDA-MD-468 (GI₅₀=107 nM). SP-96 can be used for the research of triple negative breast cancer (TNBC) .

Mirdametinib (GMP) PD0325901 (GMP); PD325901 (GMP)	Fluorescent Dye
Mirdametinib (PD0325901) (GMP) is Mirdametinib (HY-10254) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mirdametinib is an orally active, selective and non-ATP-competitive MEK inhibitor .

Mirdametinib (GMP) PD0325901 (GMP); PD325901 (GMP)	Biochemical Assay Reagents
Mirdametinib (PD0325901) (GMP) is Mirdametinib (HY-10254) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mirdametinib is an orally active, selective and non-ATP-competitive MEK inhibitor .

Hirsutenone	Classification of Application Fields Source classification Alnus cremastogyne Burk. Phenols Polyphenols Plants Disease Research Fields Inflammation/Immunology Betulaceae	PI3K ERK
Hirsutenone is an active botanical diarylheptanoid present in Alnus species and exhibits many biological activities, including anti-inflammatory, anti-tumor promoting and anti-atopic dermatitis effects. Hirsutenone attenuates adipogenesis by binding directly to PI3K and ERK1 in a non-ATP competitive manner. Hirsutenone can be used for the study of obesity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

non-ATP

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

NaturalProducts

Natural
Products